August 1988

Childhood AdrenoleukodystrophyFailure of Intensive Immunosuppression to Arrest Neurologic Progression

Author Affiliations

From the John F. Kennedy Institute (Drs Naidu and Moser and Ms O'Toole) and Departments of Neurology and Pediatrics (Drs Naidu, Griffin, and Moser), The Johns Hopkins University, Baltimore; and the Department of Neurology, Harvard University and the Children's Medical Center (Dr Bresnan), Boston.

Arch Neurol. 1988;45(8):846-848. doi:10.1001/archneur.1988.00520320032011

• Cyclophosphamide in a dosage of 350 to 700 mg/m2/d was administered for five to 11 days to four patients with childhood adrenoleukodystrophy (ALD) and to one patient with the adult cerebral form of the disease. The rate of neurologic progression in the four patients with childhood ALD did not differ from that of 167 untreated patients with childhood ALD surveyed previously.